A Phase I-II Study of PAXG in Stage III-IV Pancreatic Adenocarcinoma
Status:
Completed
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
Four-drug combo yielded a statistically significant improvement in progression-free survival
and overall survival compared to gemcitabine in patients with advanced pancreatic
adenocarcinoma. Nab-Paclitaxel showed promising antitumor activity in patients with
pancreatic cancer. Given the synergism of taxanes with gemcitabine, fluoropyrimidines and
platinating agents the role of nab-Paclitaxel in a 4-drug regimen will be explored.
The aim of this trial is to determine the recommended dose of nab-paclitaxel in combination
with cisplatin, capecitabine, and gemcitabine, PAXG regimen (Phase I), and to evaluate the
feasibility and the activity of the PAXG regimen in patients with stage III and IV pancreatic
cancer.